MX2013015409A - Diagnostico de la enfermedad de alzheimer. - Google Patents

Diagnostico de la enfermedad de alzheimer.

Info

Publication number
MX2013015409A
MX2013015409A MX2013015409A MX2013015409A MX2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A MX 2013015409 A MX2013015409 A MX 2013015409A
Authority
MX
Mexico
Prior art keywords
alzheimer
disease
diagnosis
genes
relates
Prior art date
Application number
MX2013015409A
Other languages
English (en)
Inventor
Zsuzsanna Nagy
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham filed Critical Univ Birmingham
Publication of MX2013015409A publication Critical patent/MX2013015409A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere al diagnóstico y monitoreo de la enfermedad de Alzheimer en el sujeto vivo. Más particularmente, la invención se refiere a métodos que implican la medición de la expresión genética diferencial en células no neuronales tomadas de sujetos humanos que se sospecha tienen la enfermedad de Alzheimer en donde los genes que se miden son los genes dentro de la vía de señalización mTOR.
MX2013015409A 2011-07-15 2012-07-16 Diagnostico de la enfermedad de alzheimer. MX2013015409A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1112246.2A GB201112246D0 (en) 2011-07-15 2011-07-15 Diagnosis of alzheimer's disease
PCT/GB2012/051693 WO2013011294A2 (en) 2011-07-15 2012-07-16 Diagnosis of alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2013015409A true MX2013015409A (es) 2014-03-31

Family

ID=44586710

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015409A MX2013015409A (es) 2011-07-15 2012-07-16 Diagnostico de la enfermedad de alzheimer.

Country Status (13)

Country Link
US (1) US20140295425A1 (es)
EP (1) EP2732290B1 (es)
JP (1) JP2014521315A (es)
KR (1) KR20140064779A (es)
CN (1) CN103765218A (es)
AU (1) AU2012285561A1 (es)
BR (1) BR112014000637A2 (es)
CA (1) CA2840797A1 (es)
GB (1) GB201112246D0 (es)
IL (1) IL230441A0 (es)
MX (1) MX2013015409A (es)
RU (1) RU2014105558A (es)
WO (1) WO2013011294A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10718021B2 (en) * 2014-05-28 2020-07-21 Georgetown University Genetic markers for memory loss
CN105018484B (zh) * 2015-07-31 2017-10-13 北京泱深生物信息技术有限公司 Crtap基因及其表达产物作为阿尔茨海默病的诊治靶标
CN106018827B (zh) * 2016-05-30 2018-01-16 深圳大学 一种阿尔茨海默症检测标志物及其检测方法
WO2018136702A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
KR102577154B1 (ko) * 2017-03-31 2023-09-12 뉴로디아그노스틱스 엘엘씨 알츠하이머 질환에 대한 림프구-기반 PKCε 시험
AU2018250727A1 (en) 2017-04-11 2019-10-31 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (HSD17B) family
SE543211C2 (en) 2017-06-29 2020-10-27 Mabtech Production Ab Method and system for analyzing Fluorospot assays
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
CN115078570B (zh) * 2022-05-30 2024-05-28 郑州大学第一附属医院 Tau蛋白639位硫氰酸氨基酸修饰在快速质谱法检测阿尔茨海默症中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
GB0106051D0 (en) * 2001-03-12 2001-05-02 Isis Innovation Diagnostic screens for alzheimer's disease
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
WO2009105549A2 (en) * 2008-02-19 2009-08-27 Oncomethylome Sciences Sa Detection and prognosis of lung cancer
GB0912394D0 (en) * 2009-07-16 2009-08-26 Univ Birmingham Screening methods

Also Published As

Publication number Publication date
GB201112246D0 (en) 2011-08-31
IL230441A0 (en) 2014-03-31
CA2840797A1 (en) 2013-01-24
CN103765218A (zh) 2014-04-30
KR20140064779A (ko) 2014-05-28
EP2732290B1 (en) 2016-05-25
US20140295425A1 (en) 2014-10-02
AU2012285561A1 (en) 2014-01-09
WO2013011294A2 (en) 2013-01-24
EP2732290A2 (en) 2014-05-21
BR112014000637A2 (pt) 2017-06-13
WO2013011294A3 (en) 2013-04-04
JP2014521315A (ja) 2014-08-28
RU2014105558A (ru) 2015-08-27

Similar Documents

Publication Publication Date Title
MX2013015409A (es) Diagnostico de la enfermedad de alzheimer.
EP3498729A3 (en) Therapeutic targets for alzheimer's disease
MX345230B (es) Metodos para diagnosticar patogenos de enfermedad infecciosa y su sensibilidad a farmacos.
IL242842A (en) Methods for detecting and diagnosing cardiac arrhythmias
CA2941917C (en) Methods for the diagnosis and treatment of inflammatory bowel disease
HRP20130618T1 (en) Methods of using mirna for detection of in vivo cell death
EP4219760A3 (en) Methods, compositions, and devices utilizing microrna to determine physiological conditions
NZ796092A (en) Methods for detecting signatures of disease or conditions in bodily fluids
EA201391154A2 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
BR112013001752A2 (pt) método de detectar doenças ou condições usando células fagocídicas
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
MY148484A (en) Caspase imaging probes
FR2991775B1 (fr) Diagnostic multivarie de l'etat nutritionnel des cultures
IN2014DN08398A (es)
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
HK1213753A1 (zh) 用於臨床試驗對象的疼痛的改進定量分析的訓練方法
CR20130402A (es) Unidad de interfaz y sistema de medición
IN2015DN02818A (es)
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
EP2839281A4 (en) COMPOSITIONS AND METHODS OF IDENTIFYING AND DIAGNOSIS OF SALT SENSITIVITY OF BLOOD PRESSURE
PT2526422T (pt) Método de diagnóstico da doença de sjögren
Kirpinar et al. Global assessment of functioning and associated factors in psychiatric inpatients: a retrospective study
RU2011119752A (ru) Способ оценки безопасности введения наночастиц меди в организм

Legal Events

Date Code Title Description
FA Abandonment or withdrawal